Clinical Trials Browser

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasm, Residual

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Hematologic Diseases, Multiple Myeloma

Multiple Myeloma, Neoplasms

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Plasmacytoma

Multiple Myeloma

Smoldering Multiple Myeloma, Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Clinical Trials

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

CARTITUDE-2

CARTITUDE-6

IFm2022-01

EMAT

AURIGA

MajesTEC-2

CARTITUDE-5

MonumenTAL-2

aMMbition

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

KarMMa-9

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

(COBRA)

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

QUAD

Perseus

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

KRDI in Transplant-Eligible MM

DFCI 10-106

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

MagnetisMM-7

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

DREAMM 9

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

DREAMM5

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

DRAMMATIC

IFM2017_03

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

CarBiRD

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma